Academic oncology clinicians' understanding of biosimilars and information needed before prescribing.

John W CookMegan K McGrathMargie D DixonJeffrey M SwitchenkoR Donald HarveyRebecca D Pentz

Published in: Therapeutic advances in medical oncology (2019)

Understanding of biosimilars is low, and educational needs are high. The information that clinicians deem important to assess, such as safety, efficacy and cost, will need to be provided before they are comfortable prescribing biosimilars.

Keyphrases

palliative care
primary care
health information
adverse drug
healthcare
electronic health record
drug induced